Federal Register Notice: FDA’s Anesthetic and Life Support Drugs Advisory Committee scheduled 1/28 to discuss the available safety and efficacy data for Eli Lilly’s NDA for Cymbalta capsules as they relate to the proposed indication of treatment of chronic pain is canceled. This will allow time for the agency to review new information relevant to the benefit risk balance for the proposed new indication. The agency intends to continue evaluating the application and, as needed, will announce future meeting dates in the Federal Register. To view this notice, click here.